<PAGE> 1

                              UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                          WASHINGTON, D.C. 20549

                               FORM 10-QSB


(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005.

OR

[ ]TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE TRANSITION FROM _______ TO ________.

                    COMMISSION FILE NUMBER 000-27421

                   EMERGENCY FILTRATION PRODUCTS, INC.
          ------------------------------------------------------
          (Exact name of registrant as specified in its charter)

              NEVADA                              87-0561647
   --------------------------------           -------------------
   (State or other jurisdiction of             (I.R.S. Employer
    incorporation or organization)            Identification No.)

    175 Cassia Way, Suite A115
           Henderson, Nevada                        89014
----------------------------------------          ---------
(Address of principal executive offices)          (Zip code)

Issuer's telephone number: (702) 558-5164

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes [X]    No [ ]

State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:

At June 30, 2005, there were outstanding 34,507,348 shares of the Registrant's
Common Stock, $.001 par value.

Transitional Small Business Disclosure Format: Yes [ ]   No [X]


<PAGE>
<PAGE> 2
PART I

                             FINANCIAL INFORMATION

                                  Item 1.

TABLE OF CONTENTS
                                                                 Page
                                                                 ----
Part I Financial Information

Item 1. Financial Statements

Balance Sheets
June 30, 2005 (Unaudited) and December 31, 2004..............       3

Statements of Operations (Unaudited)for the three months and
 six months ended June 30, 2005 and 2004.....................       4

Statements of Cash Flows (Unaudited)for the six months ended
 June 30, 2005 and 2004 .....................................       5

Notes to the Financial Statements............................       6

Item 2. Management's Discussion and Analysis of Financial
        Condition and Results of Operations...................      9

Item 3. Controls and Procedures...............................     14

Part II Other Information

Item 1. Legal Proceedings.....................................     15

Item 2. Unregistered Sales of Equity Securities
   and Use of Proceeds........................................     15

Item 3. Defaults by the Company on its
        Senior Securities ....................................     16

Item 4. Submission of Matter to a Vote
        Of Security Holders ..................................     16

Item 5. Other Information .....................................    16

Item 6. Exhibits...............................................    16

Signatures.....................................................    16




<PAGE>
<PAGE> 3

EMERGENCY FILTRATION PRODUCTS, INC.
Balance Sheets
June 30, 2005 and December 31, 2004
                                                    June 30,    December 31,
                                                      2005          2004
                                                   -----------   -----------
ASSETS                                             (Unaudited)
CURRENT ASSETS
 Cash and cash equivalents                        $    341,666  $    438,151
 Accounts receivable, net of an allowance for
  doubtful accounts of $8,500                           25,561         8,071
 Prepaid expenses and other                              9,046        40,342
 Inventory                                             186,789       183,275
                                                   -----------   -----------
                                                       563,062       669,839
                                                   -----------   -----------
PROPERTY AND EQUIPMENT, net of accumulated
 depreciation of $195,923 and $182,835                  97,254        66,181
                                                   -----------   -----------
OTHER ASSETS
 Patents and acquired technology, net of
  accumulated amortization of $180,257 and
  $143,097                                             934,530       971,689
 Deposits and other assets                               6,240         3,462
                                                   -----------   -----------
                                                       940,770       975,151
                                                   -----------   -----------
                                                  $  1,601,086   $ 1,711,171
                                                   ===========   ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
 Accounts payable, related parties                $    184,060   $   168,972
 Accounts payable, other                                67,987        36,522
 Accrued expenses                                       89,945        89,761
 Notes payable                                           4,747        25,479
                                                   -----------   -----------
                                                       346,739       320,734
                                                   -----------   -----------
STOCKHOLDERS' EQUITY
 Common stock, par value $0.001; authorized
  50,000,000 shares; 34,507,348 and
  33,687,848 shares issued and outstanding              34,507        33,688
 Additional paid in capital                         11,453,479    11,210,673
 Deferred compensation                                 (54,000)      (68,000)
 Accumulated other comprehensive income                 (3,162)       (7,910)
 Deficit                                           (10,176,477)   (9,778,014)
                                                   -----------   -----------
                                                     1,254,347     1,390,437
                                                   -----------   -----------
                                                   $ 1,601,086   $ 1,711,171
                                                   ===========   ===========


The accompanying notes are an integral part of these financial statements.

<PAGE>
<PAGE> 4

EMERGENCY FILTRATION PRODUCTS, INC.
Statements of Operations
For the Three Months and Six Months Ended June 30, 2005 and 2004
(Unaudited)

                      For the Three Months Ended   For the Six Months Ended
                                June 30,                    June 30,
                           2005          2004          2005           2004
                       -----------   -----------   -----------   -----------
NET SALES             $     45,842  $     64,410  $     65,811  $    325,171
                       -----------   -----------   -----------   -----------
COSTS AND EXPENSES

 Cost of sales              28,195        32,024        40,609       214,803
 Research and
  development                7,000             -         7,000             -
 Loss on vacating lease          -         8,418             -         8,418
 Selling, general
 and administrative        204,673       317,706       415,403       574,405
                       -----------   -----------   -----------   -----------
                           239,868       358,148       463,012       797,626
                       -----------   -----------   -----------   -----------
LOSS FROM OPERATIONS      (194,026)     (293,738)     (397,201)     (472,455)
                       -----------   -----------   -----------   -----------
Interest expense              (276)         (309)       (1,262)      (42,627)
                       -----------   -----------   -----------   -----------
NET LOSS              $   (194,302) $   (294,047) $   (398,463) $   (515,082)
                       ===========   ===========   ===========   ===========
BASIC AND DILUTED
 LOSS PER SHARE       $      (0.01) $      (0.01) $      (0.01) $      (0.02)
                       ===========   ===========   ===========   ===========
WEIGHTED AVERAGE
 NUMBER OF COMMON
 SHARES OUTSTANDING     34,410,645    27,479,472    34,258,450    27,372,494
                       ===========   ===========   ===========   ===========







The accompanying notes are an integral part of these financial statements.



<PAGE>
<PAGE> 5

EMERGENCY FILTRATION PRODUCTS, INC.
Statements of Cash Flows
For the Six Months Ended June 30, 2005 and 2004
(Unaudited)
                                                     2005           2004
                                                 ------------   ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
 Net loss                                       $    (398,463) $    (515,082)
 Adjustments to reconcile net loss to net
  cash used in operating activities:
  Depreciation and amortization                        50,155         56,984
  Bad debts                                                 -            500
  Common stock issued for services                     14,000              -
 Changes in operating assets and liabilities:
  Accounts receivable                                 (17,490)      (242,728)
  Prepaid expenses and other                           31,296         48,818
  Inventory                                            (3,514)        35,864
  Deposits                                             (2,778)         6,783
  Accounts payable, including to
   related parties                                     46,371        336,986
  Accrued expenses                                        184         27,779
                                                 ------------   ------------
   Net Cash Used In Operating Activities             (280,239)      (244,096)
                                                 ------------   ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
 Acquisition of property and equipment                (43,887)             -
                                                 ------------   ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
 Common stock issued through exercise
   of warrants for cash                               243,625        168,543
 Payment on notes payable                             (20,732)       (32,880)
                                                 ------------   ------------
   Net Cash Provided by Financing Activities          222,893        135,663
                                                 ------------   ------------
EFFECT OF CURRENCY EXCHANGE RATE CHANGES
 ON CASH AND CASH EQUIVALENTS                           4,748          1,473
                                                 ------------   ------------
NET DECREASE IN CASH AND CASH EQUIVALENTS             (96,485)      (106,960)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD      438,151        148,501
                                                 ------------   ------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD      $     341,666  $      41,541
                                                 ============   ============





The accompanying notes are an integral part of these financial statements.


<PAGE>
<PAGE> 6

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
June 30, 2005 and December 31, 2004

NOTE 1 - BASIS OF PRESENTATION

The interim financial information included herein is unaudited and has been
prepared consistent with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Item 310(b)
of Regulation S-B.  Accordingly, these financial statements do not include all
information required by generally accepted accounting principles for annual
financial statements.  These statements should be read in conjunction with the
audited financial statements and notes thereto included in the Company's
annual report on Form 10-KSB for the year ended December 31, 2004, from which
the balance sheet information as of that date is derived.  These interim
financial statements contain all adjustments necessary in the opinion of
management for a fair statement of results for the interim periods presented.

The results of operations for the three months and six months ended June 30,
2005, are not necessarily indicative of the results to be expected for the
full year.

Certain prior period amounts have been reclassified to conform with the
current period presentation.

NOTE 2 - LOSS PER SHARE

Following is information relative to the computation of basic and diluted loss
per share for the three months and six months ended June 30, 2005 and 2004:

                                     For the Three Months Ended
                                               June 30,
                                          2005          2004
                                      -----------   -----------
Net loss                             $   (194,302) $   (294,047)
                                      ===========   ===========
Weighted average shares                34,410,645    27,479,472
                                      ===========   ===========
Basic and diluted loss per share     $      (0.01) $      (0.01)
                                      ===========   ===========

                                     For the Six Months Ended
                                               June 30,
                                          2005          2004
                                      -----------   -----------
Net loss                             $   (398,463) $   (515,082)
                                      ===========   ===========
Weighted average shares                34,258,450    27,372,494
                                      ===========   ===========
Basic and diluted loss per share     $      (0.01) $      (0.02)
                                      ===========   ===========

Weighted average shares issuable upon the exercise of stock warrants were not
included in the foregoing calculations because they are antidilutive.

<PAGE>
<PAGE> 7

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
June 30, 2005 and December 31, 2004

NOTE 3 - GOING CONCERN CONTINGENCY

The Company's financial statements are prepared using accounting principles
applicable to a going concern. Those principles contemplate the realization of
assets and liquidation of liabilities in the normal course of business.  The
Company has incurred negative cash flow from operations and significant
losses, which have resulted in a deficit of $10,176,477 at June 30, 2005.

Consequently, the Company's ability to continue as a going concern may be
dependent upon the success of management's ongoing business plans which, as
explained below, include a) continued product development efforts, b)
continuing efforts to increase its product sales in the U.S. and
internationally, and c) seeking additional equity financing, if needed to
sustain operations until revenues are adequate to cover its costs and
expenses.

In late 2004, the Company was awarded a grant from the U.S. military to
develop a testing protocol for its nano-enhanced filter media, which was
completed in May 2005.  The funds from this grant will be paid directly to the
testing facility during the third quarter of 2005.  As a result of these
successful tests, the U.S. military is expected to begin introducing the
Company's technology to companies that manufacture filters for various
military applications with the aim of having them incorporate the technology
in their filter applications.

Throughout 2004 and early 2005, the Company had been in discussions with a
large Asian multinational company, involved in chemical and related
businesses, including air filtration, that had shown interest in a possible
distribution agreement for the Company's air filter products and technologies
in Japan.  During October 2004, the Company announced that this large Asian
company obtained a Certificate of Import and a Certificate of Sale from the
Koseisho (the Japanese Ministry of Health and Welfare, akin to the United
States Food and Drug Administration) to immediately begin importing and
selling certain of the Company's emergency respiration products in Japan.  On
December 28, 2004, the Company entered into an exclusive, long-term agreement
with this large Asian company whereby the Asian company will distribute
certain of the Company's products in Japan, once their final assessment of the
overall market for the products is completed.  The Company has provided the
Asian company with samples that incorporated certain modifications that were
requested in order to conform the Company's products to Japanese standards.
The Company is now awaiting final validation and confirmation of the last
round of modifications to the products, following which the Company expects to
commence commercial shipments to Japan.  The agreement terminates on May 31,
2008, but can be extended for an additional three-year period.  The agreement
also allows for the Asian company to form sub-distribution agreements with
other medical product companies, with the Company's approval, to promote the
sale of the Company's products in Japan.

The Company was able to raise $243,625 in additional funds during the six
months ended June 30, 2005, through the exercise of outstanding warrants to
sustain operations.  These funds have been used to retire previously
outstanding debt, to acquire additional molds for the Company's products and
for ongoing working capital.

<PAGE>
<PAGE> 8

EMERGENCY FILTRATION PRODUCTS, INC.
Notes to the Financial Statements
June 30, 2005 and December 31, 2004

NOTE 3 - GOING CONCERN CONTINGENCY (Continued)

It is management's intent to seek to create additional revenues through the
development and sales of its emergency respiration equipment and its
environmental masks.  However, management can offer no assurance with respect
to its ability to create additional revenues, obtain additional equity
financing, if needed, or otherwise execute its long-term business plans.

The accompanying financial statements do not include any adjustments relating
to the recoverability and classification of asset carrying amounts or the
amount and classification of liabilities that might result from the outcome of
this uncertainty.

NOTE 4 - STOCK WARRANTS OUTSTANDING

The Company has granted warrants to purchase common stock in conjunction with
certain stock issuances for cash.  A summary of the status of the Company's
stock warrants as of June 30, 2005, and changes during the six months then
ended, are presented below:

                                             Weighted      Weighted
                                              average       average
                                             exercise     grant date
                               Warrants        price      fair value
                              -----------   -----------   -----------
Outstanding, December 31, 2004  4,633,550   $      0.30   $         -
Exercised                        (819,500)         0.30             -
                              -----------   -----------   -----------
Outstanding, June 30, 2005      3,814,050   $      0.30   $         -
                              ===========   ===========   ===========

The outstanding warrants at June 30, 2005, are as follows:

               Number of           Exercise               Expiration
               warrants             price                    date
            -------------        ------------            ------------
                  100,000        $       0.25          April 11, 2006
                  662,800                0.25          April 23, 2006
                  226,250                0.50          May 27, 2006
                2,825,000                0.30          September 30, 2006



<PAGE>
<PAGE> 9
                                ITEM 2
Management's Discussion and Analysis of Financial Condition and Results of
Operations

Cautionary Statement Regarding Forward-looking Statements
---------------------------------------------------------
This report may contain "forward-looking" statements.  Examples of forward-
looking statements include, but are not limited to: (a) projections of
revenues, capital expenditures, growth, prospects, dividends, capital
structure and other financial matters; (b) statements of plans and objectives
of our management or Board of Directors; (c) statements of our future economic
performance; (d) statements of assumptions underlying other statements and
statements about us and our business relating to the future; and (e) any
statements using the words "anticipate," "expect," "may," "project," "intend"
or similar expressions.

Overview
--------
The Company is in the business of producing masks and filters for medical
devices that are designed to reduce the possibility of transmission of
contagious diseases.  The Company is also a distributor of a blood clotting
device for surgery, trauma and burn wound management.

Since its inception, the Company has been involved in the development of its
technology.  During this time, revenues have not been adequate to cover
operating expenses. Without adequate revenues to offset expenditures, the
Company has reported a loss in each of its years of existence.  To date, the
Company has funded itself by way of a series of private equity placements.  As
of the end of fiscal 2004, the Company had offset its accumulated deficit in
this manner. The most valuable asset of the Company is its intellectual
property and technology.  The Company has acquired the rights to certain
intellectual property, which property includes title to the patent on a
component of an emergency CPR assistance device, called a dual-filtered vapor
isolation valve and the rights to certain other technologies related to
environmental masks.  Rights pertaining thereto include the right to maintain,
sell and improve the devices, and to license those rights.  Although the
Company believes its technology to be very valuable in the economic sense,
this value is not quantified as such on the Company's balance sheet.

Results of Operations
---------------------
Six Months Ended June 30, 2005 compared with 2004
-------------------------------------------------
Revenues:  During the six months ended June 30, 2005, the Company reported a
decrease in revenues compared to the six months ended June 30, 2004 of
approximately $260,000 or 80% primarily due to the reduction in sales of the
environmental masks. This reduction in sales of the environmental masks was
due to the gradual decline in the demand for the masks in the Asian markets
and increased competition.  However, the Company expects the demand for the
environmental masks to increase in the near future due to continuing virus
outbreaks in the Far East such as SARS and Avian Influenza (Bird Flu) and has
recently started to receive numerous orders for the environmental masks.  The
Company has also recently purchased a filter cutting and sealing machine that
will enable it to rapidly produce filters and incorporate nanoparticles in its
filters at its own facilities.  In addition, during March, 2005, the Company
entered into a non-exclusive distribution agreement with a California based
company to distribute the Company's environmental masks to both retail and
wholesale market segments in the United States and internationally.  The
distributor is expected to launch a marketing campaign for the product and
seek retail outlets throughout the country (see also Liquidity and Capital
Resources below).

<PAGE>
<PAGE> 10

Revenues have also been generated in 2005 and 2004 in part from the sale of
the emergency CPR assistance device.  Sales for this product have remained
relatively constant over the past year or two, although the Company expects
that revenues for this product will increase in the near future, once the
marketing review of the Japanese market for this product is completed by
Itochu (see Liquidity and Capital Resources).

Additionally, the Company generated revenues in 2005 and 2004 related to
Superstat, a modified collagen hemostat, for which the Company has exclusive
distribution rights to the U.S. and foreign governments and militaries.
Revenues related to governmental orders of Superstat remained relatively
constant for the six months ended June 30, 2005 compared to the six months
ended June 30, 2004.  In addition to competition from other companies that may
offer alternative products, governmental orders from the military are
dependent on current foreign affairs and international conflicts and the need
for emergency products in the US military.

Cost of Sales:  During the six months ended June 30, 2005, the Company
reported a decrease in cost of sales of approximately $174,000 or
approximately 81% compared to the six months ended June 30, 2004, commensurate
with the decrease in revenues for the same period.  Costs as a percentage of
sales were 62% for the six months ended June 30, 2005 compared to 66% for the
six months ended June 30, 2004.  Costs as a percentage of sales are expected
to be slightly less than in the past due to the expected increase in sales in
foreign markets and the corresponding reduced manufacturing costs overall in
those markets. The significant components of the Company's cost of sales
include actual product cost, including outsourced manufacturing and packaging,
freight and shipping, and royalties paid on revenues generated.

Operating Expenses: During the six months ended June 30, 2005, the Company
reported a decrease in general and administrative expenses of approximately
$159,000 or approximately 28% compared to the six months ended June 30, 2004,
primarily due to the decrease in salaries and wages and other operating costs
associated with the Company's reduction in operations in Taiwan.

The Company has recently retained a consultant who will serve as Director of
Manufacturing and expects to, in the near future, incur additional operating
costs related to hiring marketing personnel for the increased business that is
expected during late 2005 related to the Itochu agreement described below in
the Liquidity and Capital Resources section.  The significant components of
our operating expenses include salaries and wages, consulting and other
professional services, product and liability insurance, travel and office
rent.

Research and development: Although not significant for the periods presented,
the Company expects research and development costs to increase somewhat in the
future because management intends to bring additional products to market
during the next year.  Future research and development costs for testing,
validation and FDA filings for these potential new products are estimated to
range from $25,000 to $35,000 during the next twelve months.  The Company
spent approximately $44,000 during the six months ended June 30, 2005, for
additional molds required for one of its new products, ELVIS (Emergency Life-
Support Ventilation and Intubation System).  An additional $30,000 to $40,000
may also be required for the production of molds for other potential new
products.  The significant components of the Company's research and
development costs ordinarily include prototype development and materials,
governmental filings and laboratory testing.

<PAGE>
<PAGE> 11

Liquidity and Capital Resources
-------------------------------
The Company has accumulated a deficit of $10,176,477 as of June 30, 2005,
resulting from the continued losses since inception.  Consequently, the
Company's ability to continue as a going concern may be dependent upon the
success of management's ongoing business plans which, as explained below,
include a) continued product development efforts, b) continuing efforts to
increase its product sales in the U.S. and internationally, and c) obtain
additional equity financing, if needed. For this and other reasons, our
auditors for our most recent fiscal year ended December 31, 2004, expressed
substantial doubt in their report as to our ability to continue operating as a
going concern.

The Company currently does not have and is not presently able to generate
sufficient net cash inflows from operations to sustain its business efforts as
well as to accommodate its growth plans.  It is management's intent to seek to
create additional revenues through the development and sales of its emergency
respiration equipment and its environmental masks through potential
distribution agreements currently being negotiated.

The Company issued 819,500 shares of common stock through the exercise of
common stock warrants during the first six months of 2005, for total proceeds
of $243,625.  In addition, the Company may receive additional funds of up to
approximately $1,151,000 through the exercise of common stock warrants
currently outstanding.

With the funds raised during 2005 and 2004, the Company intends to bring
additional products to market during the next year, including the breathing
circuit filters, the ELVIS BVM bag, and the continued marketing and
development of the personal environmental masks as previously described.  The
Company has recently retained the services of two consultants to oversee final
mold design, manufacturing and assembly of the ELVIS BVM bag and to initiate
FDA approval.  The estimated expense for this testing, validation and FDA
filings for ELVIS will be approximately $25,000. The commission of molds for
the ELVIS BVM bag will require an additional approximate amount of $20,000 to
$30,000 over the next few months.

Cash used by our operating activities for the periods ended June 30, 2005 and
2004 was funded primarily by the sale of common stock through the exercise of
common stock warrants.

The Company is continuing to focus on a marketing-driven sales effort of its
medical products and the environmental masks and associated filters,
particularly in the Asian markets, to increase revenues that will ultimately
cover total expenditures.

On March 28, 2005, the Company entered into a non-exclusive distribution
agreement with 2H Distributors, a California-based company, to distribute the
Company's environmental masks to both retail and wholesale market segments in
the United States and internationally.  2H Distributors is expected to launch
a marketing campaign during late 2005 for the product and seek retail outlets
throughout the country.  Their wholesale marketing plans entail forming
partnerships with a number of consumer products distributors in Southeast
Asian markets such as Vietnam and Thailand.

<PAGE>
<PAGE> 12

In September 2004, the Company announced that it had been awarded a Prototype
Development/Testing/Evaluation Grant (PDT&E) to develop a testing protocol for
filter media on behalf of the U.S. Military. As part of this project, the
Company tested their licensed nano-enhanced filter media at Edgewood Chemical
Biological Center in Edgewood, Maryland. The original study funded by the
grant comprised protocols or tests to evaluate the Company's filter media
efficacy against four different contaminants.  As a result of the successful
completion of this testing phase, the Company was requested by the United
States military to test its filter media against a number of additional
contaminants.  This final phase of testing was completed during May 2005.  As
a result of these successful tests, the U.S. military is expected to begin
introducing the Company's technology to companies that manufacture filters for
various military applications with the aim of having them incorporate the
technology in their filter applications.  The Company would also expect to
sub-license its nano-enhanced filter media to a number of Department of
Defense approved manufacturers to develop and/or enhance existing filtration
products that are currently used by the U.S. Air Force, Army and Navy, as well
as to commence development of new product applications that will serve to
better protect U.S. Military personnel.

On December 28, 2004, the Company entered into an exclusive, long-term
agreement with Itochu Techno Chemical, Inc. (Itochu), a Japanese corporation,
whereby Itochu will distribute the Company's Respaide, Vapor Isolation Valve
and Series One Breathing Circuit Filter products in Japan, once their final
assessment of the overall market for the Company's products is completed.
The agreement terminates on May 31, 2008, but can be extended for an
additional three-year period.  The agreement also allows for Itochu to form
sub-distribution agreements with other medical product companies, with the
Company's approval, to promote the sale of the Company's products in Japan.

During early 2005, and in conjunction with Itochu's partner/affiliate, Senko
Medical Instruments Mfg. Co. Ltd (one of Japan's leading medical products
distributors), Itochu has conducted a marketing review of the Company's
products.  This marketing review is required by Koseisho (Ministry of Health
and Welfare, similar to the United States FDA) and mandates that companies who
have been granted a certificate of import and a certificate of sale comply
fully with Japanese regulations concerning medical products.  The marketing
review will enable Itochu to make initial introductions of the products to
potential customers in Japan, to determine the potential size of the market in
Japan, and to allow the Company and Itochu to establish minimum purchase
requirement quantities applicable to the agreement for each annual period.

The Company has shipped a number of sample orders, and has modified its
products at the request of Itochu, to conform to Japanese medical product
standards.  These modifications necessitated minor but time consuming
alternations to existing molds.  As a result, this process has caused delays
in the commencement of shipping commercial orders to Itochu and its
distribution partners.  The Company has now completed all of the modifications
requested by its Japanese partners and is now awaiting final validation and
confirmation of the last round of modifications to the products, following
which the Company expects to initiate commercial shipments to Japan.  Itochu
has also expressed an interest in distributing the Company's environmental
mask product in Japan and other Pacific Rim countries that have been affected
by the Avian Influenza.

<PAGE>
<PAGE> 13

Management intends to seek to create additional revenues through the
development and sales of the Company's emergency respiration equipment and
sales of its environmental masks through potential distribution agreements
currently being negotiated in Taiwan and Japan, and to rely upon additional
equity financing, if required, to sustain operations until revenues are
adequate to cover the costs.  However, management can offer no assurance with
respect to its ability to create additional revenues, obtain additional equity
financing or execute its long-term business plans.

During its current fiscal year 2005, the Company expects that it will be able
to continue measures that will (i) reduce unnecessary cash outflows, and (ii)
increase revenues through our improved marketing efforts.

The Company's future business model is intended to be cost-efficient and will
emphasize:  (1) in-house research and development;  (2) accumulation of
intellectual property assets;  (3) ownership of key production equipment; and
(4) outsourcing of all manufacturing, distribution, warehousing, and order
fulfillment. Accordingly, the Company benefits from low overhead, as well as
the pricing advantages inherent in proprietary specialty products.

As previously discussed, our auditors for our most recent fiscal year ended
December 31, 2004, expressed substantial doubt in their report as to our
ability to continue operating as a going concern.

Impact of Inflation
-------------------
At this time, we do not anticipate that inflation will have a material impact
on our current or future operations.

Critical Accounting Policies and Estimates
------------------------------------------

Except with regard to the estimated useful lives of patents and acquired
technology, the Company does not employ any critical accounting policies or
estimates that are either selected from among available alternatives or
require the exercise of significant management judgment to apply or that if
changed are likely to materially affect future periods.  Management reviews
the carrying value of the technology assets annually for evidence of
impairment and considers, based on its current marketing activities, plans and
expectations, and the perceived effects of competitive factors and possible
obsolescence, whether any write-downs should be taken or whether the estimated
useful lives should be shortened.


<PAGE>
<PAGE> 14

Recent Accounting Pronouncements
--------------------------------

In December, 2004, the Financial Accounting Standards Board (FASB) issued SFAS
No. 123 (Revised 2004), Share-Based Payment (SFAS 123R). SFAS 123R requires
that compensation cost related to share-based employee compensation
transactions be recognized in the financial statements. Share-based employee
compensation transactions within the scope of SFAS 123R include stock options,
restricted stock plans, performance-based awards, stock appreciation rights
and employee share purchase plans. The provisions of SFAS 123R are effective
as of the first interim period that begins after December 15, 2005.
Accordingly, we will implement the revised standard no later than the first
quarter of fiscal year 2006, if applicable.

In December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary
Assets, an Amendment of APB Opinion No. 29, Accounting for Nonmonetary
Transactions.  The amendments made by SFAS 153 are based on the principle that
exchanges of nonmonetary assets should be measured based on the fair value of
the assets exchanged. Further, the amendments eliminate the narrow exception
in APB Opinion No. 29 for nonmonetary exchanges of similar productive assets
and replace it with a broader exception for exchanges of nonmonetary assets
that do not have commercial substance. The Statement is effective for
nonmonetary asset exchanges occurring in fiscal periods beginning after June
15, 2005. We do not expect to enter into any transactions that would be
affected by adopting SFAS 153 when effective.

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error
Corrections, a Replacement of APB Opinion No. 20 and SFAS No. 3.  SFAS No. 154
replaces APB Opinion No. 20, Accounting Changes and SFAS No 3, Reporting
Accounting Changes in Interim Financial Statements and changes the requirement
for the accounting for and reporting of a change in accounting principles.
SFAS No. 154 applies to all voluntary changes in accounting principles.  It
also applies to changes required by an accounting pronouncement in the unusual
instance that the pronouncement does not include specific transition
provisions.  When a pronouncement includes specific transition provisions,
those provisions should be followed.  The provisions of SFAS No. 154 will be
effective for accounting changes made in fiscal year beginning after December
15, 2005.  We do not expect that the adoption of SFAS No. 154 will have a
material impact on the Company's financial condition or operations in future
years.


                             ITEM 3.
                       CONTROLS AND PROCEDURES

Our principal executive and principal financial officers have participated
with management in the evaluation of effectiveness of the controls and
procedures required by paragraph (b) of Rule 13a-15 or Rule 15d-15 under the
Exchange Act as of the end of the period covered by this report.  Based on
that evaluation, our principal executive and principal financial officers
believe that our disclosure controls and procedures (as defined in Rule 13a-
15(e) or Rule 15d-15(e) under the Exchange Act) are effective as of the end of
the period covered by the report.  There have been no changes in our internal
controls that have materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting during the period
covered by this report.

<PAGE>
<PAGE> 15

PART II
                         OTHER INFORMATION
                     ITEM 1 - LEGAL PROCEEDINGS

There are two related legal actions currently in process in which the Company
is involved.

"Emergency Filtration Products, Inc. v. David O. Black; Michael Crnkovich;
China Bridge Holdings Ltd; and American Registrar and Transfer Company." This
case is pending in the US District Court for the District of Nevada and is
identified as CASE NO. CV-S-04-0262-KJD-LRL ("First Action"). The First Action
was initiated by the Company as plaintiff on March 5, 2004.  In the First
Action, the Company seeks Declaratory Relief under 28 USC sections 2201 and
2202 to determine the rights and obligations of the parties with respect to
certain shares of the Company's stock purportedly conveyed to David Black.  On
April 7, 2004, Black asserted counterclaims against the Company and cross
claims against American Registrar in the First Action for (1) "Breach of
Fiduciary Duty"; (2) "Constructive Conversion": (3) "Breach of Covenant of
Good Faith and Fair Dealing"; and (4) "Violation of 10(b) of the Exchange Act
of 1934."  Black's claims arise out of the Company's and American Registrar's
reluctance to register the purported transfer of the Company shares to Black.
On April 7, 2004, Black moved for partial summary judgment against the claims
asserted by the Company.  Black's motion was denied without prejudice on March
1, 2005.  On May 28, 2004, American Registrar and Transfer Company moved to
dismiss the Company's claims against it.  American Registrar's motion was
denied on March 1, 2005.  The First Action is currently in discovery.

On or about, April 15, 2004, David Black commenced a suit in the Utah Third
Judicial District Court, which is a Utah state court, against four
officers/directors of the Company (Doug Beplate, Pete Clark, Raymond Yuan, and
Sherman Lazrus) and the principal of American Registrar (Richard Day). On May
12, 2004, the action was removed to the US District Court for the District of
Utah, Central Division (federal court). The matter is captioned: "David O.
Black v. Douglas Beplate; Pete Clark, Sherman Lazrus; Raymond Yuan; Richard
Day and John Does 1 through 10," Civil Case No. 2:04CF00448 PGC ("Second
Action").  In the Second Action, Black asserts claims for (1) "Breach of
Fiduciary Duty"; (2) "Breach of Covenant of Good Faith and Fair Dealing"; and
(3) "Violation of 10(b) of the Exchange Act of 1934.  Black's claims arise out
of the identical conduct by the Company and American Registrar underlying his
counter and cross claims in the First Action.  Black's claims do not identify
any specific conduct by the individually named defendants.  Consequently,
Beplate, Clark, Yuan, and Lazrus moved to dismiss the Second Action or
transfer and consolidate the Second Action into the First Action.  On or about
September 17, 2004, the Utah District Court granted their motion and
transferred the Second Action to the U.S. District Court for the District of
Nevada. However, the Second Action and the First Action have not been
consolidated.

At this time, the outcome of these actions is uncertain, although the Company
is currently in settlement negotiations with the parties expected to be
finalized in the near future.  The Company does not expect that the settlement
will result in any liability to the Company.

   ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

  None.

<PAGE>
<PAGE> 16

           ITEM 3 - DEFAULTS BY THE COMPANY ON ITS SENIOR SECURITIES
  None.

           ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
  None.

           ITEM 5 - OTHER INFORMATION
  None.

           ITEM 6 - EXHIBITS

   Exhibit 31.1 _ Certification of principal executive officer as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002

   Exhibit 31.2 _ Certification of principal financial officer as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002

   Exhibit 32.1 - Certification of principal executive officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002

   Exhibit 32.2 - Certification of principal financial officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002



                                SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned thereunto duly
authorized.

  Emergency Filtration Products, Inc.


 Date: August 12, 2005                By: /s/Douglas K. Beplate
                                    Douglas K. Beplate, President

 Date: August 12, 2005                By: /s/Steve M. Hanni
                                    Steve M. Hanni, Chief Financial Officer